Patents by Inventor Frank M. Dyka

Frank M. Dyka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175969
    Abstract: The present disclosure provides short enhanced human opsin promoters for rod-specific expression that satisfy a need in the art for promoters that are able to control transgene expression both efficiently and selectively in rod cells, with little to no off-target expression in other photoreceptor cells. The disclosure provides vector constructs comprising transgenes operably controlled by this enhanced human opsin promoter that may be delivered and targeted with high specificity to rod cells. The disclosure also provides compositions comprising these vector constructs and methods for administration of these compositions to subjects in need thereof.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 9, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Frank M. Dyka, William W. Hauswirth
  • Publication number: 20210395778
    Abstract: Provided herein are methods and compositions for expressing Otoferlin, e.g., utilizing adeno-associated viral (AAV) particles. Further provided herein are compositions of AAV particles comprising one or more polynucleotides encoding Otoferlin are codon optimized for expression in human cells. Such methods and compositions may be useful for treatment of diseases and disorders such as Deafness, Autosomal Recessive 9 (DFNB9). Also provided are kits comprising such compositions.
    Type: Application
    Filed: November 1, 2019
    Publication date: December 23, 2021
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Frank M. Dyka, William W. Hauswirth
  • Publication number: 20210130421
    Abstract: Disclosed are materials and methods for treating diseases of the mammalian eye, and in particular, Usher syndrome 1B (USH1B). The invention provides AAV-based, dual-vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual AAV vector. In one embodiment, vector systems are provided that include i) a first AAV vector polynucleotide that includes an inverted terminal repeat at each end of the polynucleotide and a suitable promoter followed by a partial coding sequence that encodes an N-terminal portion of a full-length polypeptide: and ii) a second AAV vector polynucleotide that includes an inverted terminal repeat at each end of the polynucleotide and a partial coding sequence that encodes a C-terminal portion of a full-length polypeptide, optionally followed by a polyadenylation (pA) signal sequence.
    Type: Application
    Filed: November 18, 2020
    Publication date: May 6, 2021
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Sanford L. Boye, Shannon E. Boye, Frank M. Dyka, William W. Hauswirth
  • Publication number: 20200157573
    Abstract: Provided herein are methods and compositions for expressing Otoferlin, e.g., utilizing adeno-associated viral (AAV) particles. Such methods and compositions may be useful for treatment of diseases such as Deafness, Autosomal Recessive 9 (DFNB9).
    Type: Application
    Filed: May 4, 2018
    Publication date: May 21, 2020
    Applicants: University of Florida Research Foundation, Incorporated, The Regents of the University of California
    Inventors: Sanford L. Boye, Frank M. Dyka, William W. Hauswirth, Omar Akil